Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
RNAZ · NASDAQ · Pharmaceutical Preparations
Transcode Therapeutics (RNAZ) · oqro.io/stocks/RNAZ · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.16−0.14 (−10.77%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Transcode Therapeutics was filed in the last 90 days. The latest on record was on Sep 28, 2023.
Since 2022, Transcode Therapeutics insiders reported 9 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2023.
No open-market sale by an insider of Transcode Therapeutics (RNAZ) was filed with the SEC in the last 90 days.
No trade in Transcode Therapeutics (RNAZ) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−86.4% (−$7.40) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $8.56 on Nov 20, 2025 to $1.16 on Nov 20, 2026 (−86.4%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Boston, Ma.
Last 12 months
−86.5%
Market value
$19.6M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 52K shares sold short (0.3% of shares outstanding), −5.4% vs the previous count, 2.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Transcode Therapeutics reported 9 open-market purchases and 0 sales since 2022; purchases in 2 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2023 | $176K5×5 trades | — |
| 2022 | $94K4×4 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in advanced solid tumor.
1 trial has a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 13,000 words.
TransCode is an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy. Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Polynoma Acquisition. On October 8, 2025, we entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with DEFJ, LLC, a Delaware limited liability company, (“DEFJ”) pursuant to which we acquired 100% of the issued and outstanding membership interests of ABCJ, LLC, a Delaware limited liability company, (“ABCJ”) (such transaction, the “Acquisition”).
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Apr 15, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Against the S&P 500 over the year
Since Nov 14, 2025, RNAZ is down 87.4% and the index fund is up 2.7%: 90 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much RNAZ moves
Beta 0.8 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 245 trading days (1 = in step with it).
No Schedule 13D or 13G filing on RNAZ over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Debt came due early or grew after a triggering event
8-K on sec.govTop officer leaving
“Departure of Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Director On September 10, 2026, TransCode Therapeutics, Inc.”
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K/A on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govSaid its annual or quarterly report would be late
NT 10-K on sec.govTop officer leaving
“CEO Appointment and One-Time Bonuses On October 6, 2025, the Board accepted Thomas Fitzgerald’s resignation as Interim Chief Executive Officer of the Company and appointed Dr.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Off-exchange trading: 56.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (5.0% on ATS, 51.3% with other brokers), above its 26-week average of 49.5%. Weeks of Sep 21 to Oct 16, 2026.
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $4.64M, at Sep 30, 2026
Net income, last 12 months
−$145M
Operating loss: profit did not cover interest (latest fiscal year)
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Apr 5, 2024.
Revenue and earnings history, 6 fiscal yearsEarnings dates and the stock's moves
Largest ATS: UBS ATS (14.1%), IBKR ATS (11.6%), SIGMA X2 (10.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Latest annual report filed Apr 15, 2026, compared with the one filed Apr 15, 2025. Read the filing
And 2 more headings in the filing.
From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. We do not know of any claims or actions pending against us or threatened, the ultimate disposition of which could have a material adverse effect on our consolidated results of operations or consolidated financial condition except claims by an investment bank that it is entitled to fees, claims which we have rigorously disputed.
Source: SEC EDGAR, Form 10-K filed Apr 15, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.